Exhibit 99.1
21 December 2016
Motif Bio plc
(“Motif Bio” or the “Company”)
Result of GM
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that all resolutions put to shareholders at the Company’s General Meeting held earlier today were duly passed.
For further information please contact:
Motif Bio plc |
| info@motifbio.com |
Graham Lumsden (Chief Executive Officer) |
|
|
|
|
|
Zeus Capital Limited (NOMAD & BROKER) |
| +44 (0)20 3829 5000 |
Phil Walker/Giles Balleny |
|
|
Dominic Wilson |
|
|
|
|
|
Northland Capital Partners Limited (BROKER) |
| +44 (0)203 861 6625 |
Patrick Claridge/ David Hignell |
|
|
John Howes/ Rob Rees (Broking) |
|
|
|
|
|
Walbrook PR Ltd. (FINANCIAL PR & IR) |
| +44 (0) 20 7933 8780 or motifbio@walbrookpr.com |
Paul McManus |
| Mob: +44 (0)7980 541 893 |
Mike Wort |
| Mob: +44 (0)7900 608 002 |
|
|
|
MC Services AG (EUROPEAN IR) |
| +49 (0)89 210 2280 |
Raimund Gabriel |
|
|